This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Jan 28;379(9813):291-2.

doi: 10.1016/S0140-6736(11)61928-4. Epub 2012 Jan 7.

Adjuvant therapy for gastric cancer after D2 gastrectomy

Toshirou Nishida¹

Affiliations

PMID: 22226518
DOI: 10.1016/S0140-6736(11)61928-4

Comment

Adjuvant therapy for gastric cancer after D2 gastrectomy

Toshirou Nishida. Lancet. 2012.

. 2012 Jan 28;379(9813):291-2.

doi: 10.1016/S0140-6736(11)61928-4. Epub 2012 Jan 7.

Author

Toshirou Nishida¹

Affiliation

¹ Department of Surgery, Osaka Police Hospital, Osaka 543-0035, Japan. toshin@mvb.biglobe.ne.jp

PMID: 22226518
DOI: 10.1016/S0140-6736(11)61928-4

No abstract available

PubMed Disclaimer

Comment on

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators. Bang YJ, et al. Lancet. 2012 Jan 28;379(9813):315-21. doi: 10.1016/S0140-6736(11)61873-4. Epub 2012 Jan 7. Lancet. 2012. PMID: 22226517 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information